CN113575946A - A composition for inhibiting absorption of sugar and fat - Google Patents
A composition for inhibiting absorption of sugar and fat Download PDFInfo
- Publication number
- CN113575946A CN113575946A CN202110841979.5A CN202110841979A CN113575946A CN 113575946 A CN113575946 A CN 113575946A CN 202110841979 A CN202110841979 A CN 202110841979A CN 113575946 A CN113575946 A CN 113575946A
- Authority
- CN
- China
- Prior art keywords
- extract containing
- composition
- fat absorption
- sugar
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 49
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 47
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 76
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 76
- 244000269722 Thea sinensis Species 0.000 claims abstract description 30
- 241000220317 Rosa Species 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 27
- 229940094952 green tea extract Drugs 0.000 claims abstract description 27
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 27
- 235000013616 tea Nutrition 0.000 claims abstract description 27
- 229920000241 Punicalagin Polymers 0.000 claims abstract description 25
- 229940054168 pomegranate fruit extract Drugs 0.000 claims abstract description 25
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 claims abstract description 25
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 claims abstract description 25
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 241000219991 Lythraceae Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 22
- 102000004139 alpha-Amylases Human genes 0.000 abstract description 22
- 108090000637 alpha-Amylases Proteins 0.000 abstract description 22
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 22
- 229940024171 alpha-amylase Drugs 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 22
- 230000005764 inhibitory process Effects 0.000 abstract description 21
- 239000004367 Lipase Substances 0.000 abstract description 11
- 102000004882 Lipase Human genes 0.000 abstract description 11
- 108090001060 Lipase Proteins 0.000 abstract description 11
- 235000019421 lipase Nutrition 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 45
- 239000007853 buffer solution Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 229940040461 lipase Drugs 0.000 description 9
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 7
- 229960002632 acarbose Drugs 0.000 description 7
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 244000046052 Phaseolus vulgaris Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229940054810 white kidney bean extract Drugs 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000003392 amylase inhibitor Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YNGNVZFHHJEZKD-UHFFFAOYSA-N (4-nitrophenyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 YNGNVZFHHJEZKD-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000003421 catalytic decomposition reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for inhibiting sugar and fat absorption, which comprises less than 94% of green tea extract containing tea polyphenol, 3% -20% of rose extract containing polyphenol and more than 3% of pomegranate fruit extract containing polyphenol and punicalagin by weight. The composition for inhibiting sugar and fat absorption prepared by the invention can realize double inhibition on alpha-amylase and alpha-glucosidase, and simultaneously can inhibit the activity of lipase, thereby further achieving the effect of reducing fat. The composition can remarkably improve the bitter taste of the green tea extract containing tea polyphenol, improve the taking experience of eaters and enhance the willingness of the eaters to take for a long time. The composition has the advantages of clear components and effects, wide application range, no toxic or side effect, simple preparation operation, low cost, wide applicable dosage form and convenient production and application.
Description
Technical Field
The invention belongs to the technical field of food, and particularly relates to a composition for inhibiting sugar and fat absorption.
Background
With the development of economic society, the intake of sugar and fat of modern people is continuously increased, the intake of energy is far larger than the consumption of energy, and the reduction of exercise amount at ordinary times causes the accumulation of fat in the body to be excessive and the fat-leading rate to be continuously increased. Obesity can cause various cardiovascular and cerebrovascular diseases of human bodies, and the life quality is obviously reduced.
Orlistat is the most commonly used weight loss drug approved by the FDA in the united states. It is an effective lipase inhibitor, and mainly can reduce the absorption and utilization rate of fat ingested by human body by inhibiting the biological activity of pancreatic lipase so as to attain the effect of reducing weight and reducing blood fat. Orlistat also has certain side effects that can affect the absorption of fat soluble vitamins a and E. Sibutramine (sibutramine) can inhibit the reuptake of norepinephrine and serotonin by central neurons, inhibit appetite, increase satiety of an organism, increase excitability of central sympathetic efferent nerves, increase energy consumption and achieve the aim of reducing weight, but sibutramine can also cause heart rate acceleration and blood pressure rise. Phentermine (Phentermine) is an effective weight-losing medicine, belongs to amphetamine medicines, achieves the weight-losing effect mainly by suppressing appetite, but can also influence the central nervous system and the cardiovascular system of a body, so that the heartbeat of a user is accelerated, the user is stressed, the user has insomnia and the like.
With the development of socioeconomic in China, the health diet consciousness of people is improved, and the nutrition and health care function of food are more and more paid attention by people. In the face of increasing incidence of globally serious obesity and metabolic diseases caused by obesity, a safe and effective novel prevention and treatment strategy is searched, and the method has important significance for intervening obesity-related health diseases and reducing incidence of obesity and obesity-related diseases.
Research proves that metabolic syndrome is closely related to unreasonable diet, and the intervention of fat metabolism in vivo through diet becomes one of the latest research hotspots. Therefore, a safe weight-losing method is searched from a food-derived natural product, a functional factor with the function of fat metabolism intervention in vivo is developed, and the research on the application of the functional factor in preventing and treating metabolic syndrome has important economic and social values.
The functional food is a special food with specific health care function, conforms to the basic constitution of the food and has corresponding functions. The functional food hot tide brings new development opportunities for the food industry in China. The search for safe and effective natural substances to intervene in obesity development is the current research focus. Inhibition of sugar and fat absorption are important aspects of natural products in interfering with the development of obesity.
Fat ingested in food is hydrolyzed by gastric, pancreatic and intestinal lipases into monoglyceride and Free Fatty Acid (FFA), which are absorbed in the intestinal tract, synthesized again into fat in vivo, and stored under the skin and around the internal organs of the body, causing excessive accumulation of fat, resulting in obesity. The lipase inhibitor can effectively inhibit the catalytic decomposition of lipase on fat, reduce the absorption of fat and achieve the aim of preventing and treating obesity. A plurality of safe lipase inhibitors with small toxic and side effects exist in natural products.
Alpha-glucosidase and alpha-amylase are key glycoside hydrolases that affect the digestion and absorption of carbohydrates such as starch. After the carbohydrate is ingested, the carbohydrate is hydrolyzed into oligosaccharide under the action of small intestine alpha-amylase, and then is hydrolyzed into glucose under the action of alpha-glucosidase, so that the blood sugar is increased. Therefore, inhibition of the activity of these two enzymes, delaying carbohydrate digestion and the rate of glucose entry into the blood, is considered to be an effective way to control postprandial hyperglycemia. At present, commonly used alpha-amylase and alpha-glucosidase activity inhibition drugs, such as acarbose, miglitol and the like, can cause flatulence, diarrhea, abdominal diseases and liver diseases of a human body, so that the search for a natural enzyme activity inhibition component with small side effect becomes one of research hotspots for obesity intervention.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, it is an object of the present invention to provide a composition for inhibiting absorption of sugar and fat; the composition for inhibiting sugar and fat absorption comprises green tea extract containing tea polyphenols less than 94 wt%, rose extract containing polyphenols 3-20 wt%, and pomegranate fruit extract containing polyphenols and punicalagin more than 3 wt%.
Preferably, the composition for inhibiting sugar and fat absorption comprises 10-94% by weight of green tea extract containing tea polyphenols, 3-10% by weight of rose extract containing polyphenols and 3-87% by weight of pomegranate fruit extract containing polyphenols and punicalagin.
Preferably, the composition for inhibiting sugar and fat absorption comprises 20-94 wt% of green tea extract containing tea polyphenols, 3-10 wt% of rose extract containing polyphenols and 3-77 wt% of pomegranate fruit extract containing polyphenols and punicalagin.
Preferably, the composition for inhibiting sugar and fat absorption comprises 30-94 wt% of green tea extract containing tea polyphenols, 3-10 wt% of rose extract containing polyphenols and 3-67 wt% of pomegranate fruit extract containing polyphenols and punicalagin.
Furthermore, the composition for inhibiting sugar and fat absorption also comprises auxiliary materials or additives used in medicines and foods, wherein the auxiliary materials or additives are one or more of sweetening agents, acid regulators, fillers, flavoring agents, coloring agents, antioxidants, thickening agents, stabilizing agents, emulsifying agents, anticaking agents, glidants and lubricating agents.
Further, the extraction method of the green tea extract containing tea polyphenol comprises the following steps:
pulverizing green tea, extracting with water or ethanol, concentrating, and drying to obtain green tea extract containing tea polyphenols.
Further, the extraction method of the rose extract containing polyphenol comprises the following steps:
the rose is crushed, extracted by water or ethanol, concentrated and dried to obtain the rose extract containing polyphenol.
Further, the extraction method of the pomegranate fruit extract containing polyphenol and punicalagin comprises the following steps:
pulverizing pomegranate fruit, extracting with water or ethanol, concentrating, and drying to obtain pomegranate fruit extract containing polyphenol and punicalagin.
Further, the composition for inhibiting sugar and fat absorption is an oral preparation.
Further, the oral preparation is powder, granules, hard capsules, soft capsules, tablets, soft sweets, oral solution or emulsion.
Compared with the prior art, the invention has the following beneficial effects:
(1) the existing sugar and fat control products are widely applied to white kidney bean extracts, but the white kidney bean extracts only can inhibit alpha-amylase to a certain extent, but cannot control the alpha-glucosidase. Both alpha-amylase and alpha-glucosidase can decompose polysaccharides, but the complete control of sugar absorption cannot be achieved by simply inhibiting one of the enzymes. According to the invention, the double inhibition of alpha-amylase and alpha-glucosidase can be realized through the scientific proportion of the rose extract containing polyphenol, the pomegranate fruit extract containing polyphenol and punicalagin and the green tea extract containing tea polyphenol.
(2) The composition for inhibiting sugar and fat absorption prepared by the invention can also inhibit the activity of lipase at the same time, thereby further achieving the effect of reducing fat.
(3) According to the invention, the bitter taste of the green tea extract containing tea polyphenol can be obviously improved through the scientific proportion of the rose extract containing polyphenol, the pomegranate fruit extract containing polyphenol and punicalagin and the green tea extract containing tea polyphenol. Improves the taking experience of eaters and enhances the willingness of the eaters to take for a long time.
(4) The composition for inhibiting the absorption of sugar and fat prepared by the invention has the advantages of clear components and effects, wide application range, no toxic or side effect, simple preparation operation, low cost, wide applicable dosage form and convenient production and application.
Drawings
FIG. 1 is a bar graph of α -amylase activity inhibition.
FIG. 2 is a bar graph showing the inhibition rate of alpha-glucosidase activity.
FIG. 3 is a bar graph showing the inhibition rate of pancreatic lipase activity.
FIG. 4 is a graph of fat accumulation oil red staining of 3T3-L1 cells.
FIG. 5 shows the OD values of 3T3-L1 cells after oil red staining.
Detailed Description
In order to make those skilled in the art better understand the technical solution of the present invention, the technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention and the drawings in the embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
An extraction process of green tea extract containing tea polyphenols is provided.
The detailed steps comprise pulverizing green tea, extracting with water or ethanol, concentrating, and drying to obtain green tea extract containing tea polyphenols
An extraction process of rose extract containing polyphenol.
In the detailed steps, the rose is crushed, extracted by water or ethanol, concentrated and dried to obtain the rose extract containing polyphenol.
A process for extracting pomegranate fruit extract containing polyphenol and punicalagin is provided.
The detailed steps are that the pomegranate fruit is crushed, extracted by water or ethanol, concentrated and dried to obtain the pomegranate fruit extract containing polyphenol and punicalagin.
This example provides compositions that inhibit sugar and fat absorption and methods for their preparation.
(1) Composition for inhibiting sugar and fat absorption.
TABLE 1 weight part composition of compositions for inhibiting sugar and fat absorption
(2) A method for preparing composition for inhibiting sugar and fat absorption is provided.
The substances are uniformly mixed according to the weight parts shown in the following table 1 to obtain the composition for inhibiting the absorption of sugar and fat.
Alpha-amylase activity assay:
(1) weighing Na2HPO415.63g and 10.80g KH2PO4Dissolving with 1000ml pure water, adjusting pH to 6.9 with HCl to obtain 0.2M PBS bufferAnd (4) liquid.
(2) Taking a proper amount of alpha-amylase, preparing 5unit/mL alpha-amylase solution by using PBS buffer solution, dissolving, and then placing in a water bath at 37 ℃ for activation for later use.
(3) 1g of soluble starch is accurately weighed, mixed evenly with a small amount of PBS buffer solution, poured into boiled PBS buffer solution, heated to be boiled to be transparent, and cooled to be 100 mL. A 1% soluble starch solution was prepared.
(4) Acarbose solution: taking acarbose tablets (50 mg/tablet of Bendazine), grinding by using a mortar, adding PBS buffer solution to prepare 1mg/mL acarbose solution, and diluting according to the required concentration.
(5) Sample group: the compositions obtained in each example and comparative example were dissolved in PBS buffer to prepare a 10mg/mL component solution.
(6) White kidney bean solution: dissolving white kidney bean with PBS buffer solution to obtain 10mg/ml white kidney bean solution
(7) Sample adding:
a. sample group: 50. mu.L of each of the comparative ingredient solutions of examples and comparative examples was added to an EP tube, and 50. mu.L of an alpha-amylase solution was added thereto.
Positive reference group: add 50. mu.L of acarbose solution to the EP tube and add 50. mu.L of alpha-amylase solution.
White kidney bean extract reference group: adding 50 μ L acarbose solution into EP tube, dissolving 100 parts of semen Phaseoli vulgaris extract with PBS buffer solution to obtain 10mg/mL component solution, adding into EP tube, and adding 50 μ L alpha-amylase solution.
Negative reference group: add 50. mu.L of LPBS buffer to the EP tube and add 50. mu.L of alpha-amylase solution.
Blank reference group: add 100. mu.L of LPBS buffer to the EP tube.
b. All tubes were reacted at 37 ℃ for 15 min.
c. 400 μ L of 1% soluble starch solution was added to all tubes and reacted in a water bath at 37 ℃ for exactly 10min, followed immediately by a boiling water bath for 10 min.
d. 1mL of DNS developer was added to all tubes, reacted for 5min in a boiling water bath, and immediately cooled to room temperature in cold water.
e. 1mL of the reaction solution in each tube was transferred, diluted with 4mL of pure water, and the absorbance value was measured at 540nm using a spectrophotometer.
(8) Data analysis
The alpha-amylase inhibition rate calculation formula is as follows:
α -amylase inhibition ═ 100% x [ (a negative-a blank) - (a sample-a blank) ]/(a negative-a blank).
As shown in FIG. 1, the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 and comparative examples 10 to 11 had similar α -amylase inhibitory function to that of the positive reference group acarbose; the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 had significantly better α -amylase inhibition than the white kidney bean extract; the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 have better inhibition rate of alpha-amylase than the compositions for inhibiting sugar and fat absorption prepared in comparative examples 10 to 11, which shows that the green tea extract containing tea polyphenol, the rose extract containing polyphenol and the pomegranate fruit extract containing polyphenol and punicalagin have more excellent inhibition rate of alpha-amylase after being compounded according to a certain proportion. In addition, the larger the ratio of pomegranate fruit extract containing polyphenol and punicalagin to green tea extract containing tea polyphenol, the stronger the alpha-amylase inhibitory effect of the composition.
Alpha-glucosidase activity assay:
(1) weighing Na2HPO412.24g and 13.93g KH2PO41000ml of purified water was added thereto to dissolve the resulting solution, and the pH was adjusted to 6.8 with HCl, to obtain 0.2M PBS buffer.
(2) 45mg of PNPG was weighed and dissolved in 15mL of pure water to obtain a 10mM 4-nitrophenyl-alpha-D-glucopyranoside solution.
(3) 1.06g of sodium carbonate is weighed and dissolved in pure water, and the volume is determined to be 100mL, thus obtaining 0.2M sodium carbonate solution.
(4) Weighing a certain amount of alpha-glucosidase, shaking and dissolving the alpha-glucosidase by using 0.1M PBS buffer solution to obtain 50U/mL alpha-glucosidase, and storing the alpha-glucosidase in a refrigerator at the temperature of 20 ℃ below zero for later use. When in use, 0.1mL of 50U/mL alpha-glucosidase is quantified to 25mL by 0.1MPBS buffer solution, and 0.2U/mL of alpha-glucosidase is obtained.
(5) The compositions obtained in the examples and comparative examples were added to PBS buffer to prepare 10mg/mL component solutions.
(6) Adding PBS buffer solution into white kidney bean extract to obtain 10mg/mL component solution.
(7) Sample application
Sample group: 25 μ L of each of the examples and comparative component solutions and 25 μ L0.2U/mL of α -glucosidase were incubated at 37 ℃ for 15 minutes.
White kidney bean extract reference group: adding PBS buffer solution into 100 parts of white kidney bean extract, making into 10mg/mL white kidney bean solution 25uL and 25 μ L0.2U/mL alpha-glucosidase component solution, and culturing at 37 deg.C for 15 min.
Negative reference group: mu.L of 0.2M PBS buffer was added, and 25. mu.L of glucosaccharase was incubated at 37 ℃ for 15 minutes.
Blank reference group: 50 μ L of 0.2M PBS buffer was added and incubated at 37 ℃ for 10 minutes.
mu.L of 2.5mM PNPG was added to all groups, and the mixture was reacted at 37 ℃ for 20 minutes, followed by addition of 100. mu.L of 0.2M sodium carbonate solution, followed by uniform mixing, and absorbance measurement at 405nm using a microplate reader.
(8) Data analysis
The alpha-glucosidase inhibition rate calculation formula is as follows:
α -glucosidase inhibition ═ [ (a negative-a blank) - (a sample-a blank) ]/(a negative-a blank) × 100%
As shown in fig. 2, the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 have significantly better inhibition rate on α -glucosidase than the white kidney bean extract; the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 have better alpha-glucosidase inhibition rate than the compositions for inhibiting sugar and fat absorption prepared in comparative examples 10 to 11, which shows that the green tea extract containing tea polyphenol, the rose extract containing polyphenol and the pomegranate fruit extract containing polyphenol and punicalagin have more excellent inhibition rate on alpha-glucosidase after being compounded in a specific ratio.
And (3) lipase activity determination:
(1) 41mg of sodium acetate was weighed, dissolved in 100mL of distilled water, and 1mL of Triton X-100 was added to obtain a 5mM sodium acetate solution. 80mg of 4-nitrophenyldodecanoate was dissolved in 100ml of 5mM sodium acetate solution containing 1% Triton X-100, and the solution was stirred at 65 ℃ for 15min to mix well, thereby obtaining pNP laurate solution.
(2) 4.8456g are weighed
Dissolving base in 200mL of distilled water, then dropwise adding 0.1M HCl, adjusting the pH to 8.2, then adding pure water, roughly fixing the volume to 400mL, and obtaining 0.1M Tris-HCl buffer solution.
(3) Transferring 50 mu L of pancreatic lipase to a 20mL volumetric flask, adding 0.1M Tris-HCl buffer solution, and uniformly mixing to obtain a lipase solution.
(4) The compositions obtained in each example and comparative example were added to 0.1M Tris-HCl buffer to prepare 10mg/mL component solutions.
(5) Sample adding:
a. all groups were initially loaded with 200. mu.L Tris-HCl buffer
b. Sample group: 100 μ L of each example and comparative ingredient solutions and 100 μ L of lipase solution were added to the EP tube.
Positive reference group: 0.05mg/mL of 100. mu.L orlistat solution 100. mu.L, 100. mu.L lipase solution was added to the EP tube.
Negative reference group: mu.L of Tris-HCl buffer, 100. mu.L of lipase solution were added to the EP tube.
Blank reference group: 200 μ L Tris-HCl buffer was added to the EP tube
c. All EP tubes were placed in a 37 ℃ water bath for 15 min.
d. All EP tubes were reacted for 30min at 37 ℃ with 200. mu.L of pNP laurate solution.
e. The reaction was then terminated by placing all tubes in a water bath at 95 ℃ for 5 min. After cooling to room temperature, all tubes were centrifuged at 6000rpm for 3 min. Transfer 200. mu.L of supernatant to a 96-well plate and measure absorbance at 405 nm.
(6) Data analysis
The pancreatic lipase inhibition rate calculation formula is as follows:
the results of the pancreatic lipase inhibition rate [ (a negative-a blank) - (a sample-a blank) ]/(a negative-a blank) × 100% are shown in fig. 3, and the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 and orlistat had similar lipase inhibition effects; the lipase inhibition ratios of the compositions for inhibiting sugar and fat absorption prepared in examples 1 to 9 are superior to those of the compositions for inhibiting sugar and fat absorption prepared in comparative examples 10 to 11, which shows that the green tea extract containing tea polyphenol, the rose extract containing polyphenol and the pomegranate fruit extract containing polyphenol and punicalagin have more excellent lipase inhibition ratios after being compounded according to specific proportions.
3T3-L1 assay for fat accumulation:
(1)3T3-L1 cell induced differentiation
Inoculating 3T3-L1 preadipocytes to a culture plate, culturing with high glucose DMEM containing 10% fetal calf serum at 37 deg.C and 5% CO2Culturing under the condition, digesting the cells with pancreatin when the cells grow to 80% -90%, and preparing cell suspension (day 0).
(2) Adding inducer I and culturing for 2 days.
The formula of the inducer I comprises the following components: 3-isobutyl-1-methylxanthine was made up to 0.5mol/L in ethanol, dexamethasone was made up to 2.5mmol/L in ethanol, 10mg of insulin was dissolved in 1mL of 0.01mol/L HCl.
(3) Adding inducer II and culturing for 2 days.
The formula of the inducer II comprises: 10% fetal bovine serum, 0.5 mmol/L3-isobutyl-1-methylxanthine, 1. mu. mol/L dexamethasone, 5. mu.g/mL insulin.
(4) Day 5 of differentiation
The cells were divided into a blank group (culture medium), 50 μ g/mL rose extract group containing polyphenols, 50 μ g/mL pomegranate fruit extract group containing polyphenols and punicalagin, 50 μ g/mL green tea extract group containing tea polyphenols, 50 μ g/mL composition group (10% rose extract containing polyphenols + 45% pomegranate fruit extract containing polyphenols and punicalagin + 45% green tea extract containing tea polyphenols), and positive reference group (lithium chloride).
Meanwhile, culturing for 48h by using high-glucose DMEM, then changing 10% fetal calf serum high-glucose DMEM culture solution containing insulin with the final mass concentration of 10 mu g/mL, continuously culturing for 48h, changing the solution 1 time every 2d, and finishing the experiment after 9 days.
(5) Oil red dyeing
Removing the culture medium of the treated cells, and washing the cells twice by using cold PBS; fixing the cells with 4% paraformaldehyde solution for 60 min; dyeing the fixed cells by using an oil red O dye solution kit; cells were washed 3 times with 60% isopropanol to remove uncolored oil red O stain and photographed under a microscope. The experimental results are shown in fig. 4, and the composition group has significantly reduced staining degree compared to the blank group, the rose extract group containing polyphenol, the pomegranate fruit extract group containing polyphenol and punicalagin, and the green tea extract group containing tea polyphenol, and is almost equivalent to the positive control.
(6) Data analysis
After the observation was completed, the lysate (containing 4% NP-40) lysed the cells and the OD was determined at 490 nm. The experimental results are shown in fig. 5, according to the OD value of oil red staining, the composition group was significantly reduced compared to the blank group, the rose extract group containing polyphenol, the pomegranate fruit extract group containing polyphenol and punicalagin, and the green tea extract group containing tea polyphenol, and there was a significant difference (P < 0.05). The composition can enhance the effect of inhibiting fat accumulation after being compounded in a specific proportion.
Finally, it should be noted that the above-mentioned embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the same, and although the present invention is described in detail with reference to the above-mentioned embodiments, it should be understood by those skilled in the art that the modifications and equivalents of the specific embodiments of the present invention can be made by those skilled in the art after reading the present specification, but these modifications and variations do not depart from the scope of the claims of the present application.
Claims (10)
1. A composition for inhibiting sugar and fat absorption comprises less than 94% by weight of green tea extract containing tea polyphenols, 3% -20% by weight of rose extract containing polyphenols, and more than 3% by weight of pomegranate fruit extract containing polyphenols and punicalagin.
2. The composition for inhibiting sugar and fat absorption according to claim 1, wherein the composition for inhibiting sugar and fat absorption comprises 10% to 94% by weight of green tea extract containing tea polyphenols, 3% to 10% by weight of rose extract containing polyphenols and 3% to 87% by weight of pomegranate fruit extract containing polyphenols and punicalagin.
3. The composition for inhibiting sugar and fat absorption according to claim 1, wherein the composition for inhibiting sugar and fat absorption comprises 20% to 94% by weight of green tea extract containing tea polyphenols, 3% to 10% by weight of rose extract containing polyphenols and 3% to 77% by weight of pomegranate fruit extract containing polyphenols and punicalagin.
4. The composition for inhibiting sugar and fat absorption according to claim 1, wherein the composition for inhibiting sugar and fat absorption comprises 30% to 94% by weight of green tea extract containing tea polyphenols, 3% to 10% by weight of rose extract containing polyphenols and 3% to 67% by weight of pomegranate fruit extract containing polyphenols and punicalagin.
5. The composition for inhibiting sugar and fat absorption according to any one of claims 1 to 4, further comprising an adjuvant or additive used in drugs and foods, wherein the adjuvant or additive is one or more of a sweetener, an acid regulator, a filler, a flavoring agent, a coloring agent, an antioxidant, a thickener, a stabilizer, an emulsifier, an anticaking agent, a glidant and a lubricant.
6. The composition for inhibiting sugar and fat absorption according to any one of claims 1 to 4, wherein the green tea extract containing tea polyphenol is extracted by the following method:
pulverizing green tea, extracting with water or ethanol, concentrating, and drying to obtain green tea extract containing tea polyphenols.
7. The composition for inhibiting sugar and fat absorption according to any one of claims 1 to 4, wherein the extraction method of the rose extract containing polyphenol is as follows:
the rose is crushed, extracted by water or ethanol, concentrated and dried to obtain the rose extract containing polyphenol.
8. The composition for inhibiting sugar and fat absorption according to any one of claims 1 to 4, wherein the pomegranate fruit extract containing polyphenol and punicalagin is extracted by the following method:
pulverizing pomegranate fruit, extracting with water or ethanol, concentrating, and drying to obtain pomegranate fruit extract containing polyphenol and punicalagin.
9. The sugar and fat absorption inhibiting composition according to any one of claims 1 to 4, wherein the sugar and fat absorption inhibiting composition is an oral preparation.
10. The composition for inhibiting sugar and fat absorption according to claim 9, wherein the oral formulation is a powder, a granule, a hard capsule, a soft capsule, a tablet, a soft candy, an oral solution, or an emulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110841979.5A CN113575946B (en) | 2021-07-26 | 2021-07-26 | A composition for inhibiting sugar and fat absorption |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110841979.5A CN113575946B (en) | 2021-07-26 | 2021-07-26 | A composition for inhibiting sugar and fat absorption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113575946A true CN113575946A (en) | 2021-11-02 |
| CN113575946B CN113575946B (en) | 2024-06-14 |
Family
ID=78249899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110841979.5A Active CN113575946B (en) | 2021-07-26 | 2021-07-26 | A composition for inhibiting sugar and fat absorption |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113575946B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113896751A (en) * | 2021-11-19 | 2022-01-07 | 成都农业科技中心 | Punicalagin purification method and application thereof in preparation of alpha-glucosidase inhibitor |
| CN115769893A (en) * | 2022-12-02 | 2023-03-10 | 中南林业科技大学 | Polyphenol additive capable of reducing glycemic index of food and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3966689B2 (en) * | 2000-12-15 | 2007-08-29 | 株式会社ファンケル | Lipase inhibitor |
| US20120269790A1 (en) * | 2009-09-23 | 2012-10-25 | Penalver Mellado Marcos | Use of plant extracts as prebiotics, compositions and foods containing such extract |
| CN103504040A (en) * | 2013-09-29 | 2014-01-15 | 闵永祥 | Rose green tea |
| CN103652050A (en) * | 2013-11-14 | 2014-03-26 | 安徽天思食品有限公司 | Pomegranate green tea drink and preparation method thereof |
| CN109953145A (en) * | 2017-12-23 | 2019-07-02 | 宜兴市瑞优娜玫瑰产业有限公司 | A kind of preparation method of rose tea |
| CN111629742A (en) * | 2017-11-20 | 2020-09-04 | 株式会社爱茉莉太平洋 | Composition comprising green tea extract with increased polysaccharide content as active ingredient |
| CN112106856A (en) * | 2020-08-31 | 2020-12-22 | 曲水净土玫瑰产业开发有限公司 | Preparation method of rose black tea solid beverage |
| CN112996526A (en) * | 2018-11-05 | 2021-06-18 | 株式会社爱茉莉太平洋 | Green tea extract with variable component content and composition containing the same |
-
2021
- 2021-07-26 CN CN202110841979.5A patent/CN113575946B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3966689B2 (en) * | 2000-12-15 | 2007-08-29 | 株式会社ファンケル | Lipase inhibitor |
| US20120269790A1 (en) * | 2009-09-23 | 2012-10-25 | Penalver Mellado Marcos | Use of plant extracts as prebiotics, compositions and foods containing such extract |
| CN103504040A (en) * | 2013-09-29 | 2014-01-15 | 闵永祥 | Rose green tea |
| CN103652050A (en) * | 2013-11-14 | 2014-03-26 | 安徽天思食品有限公司 | Pomegranate green tea drink and preparation method thereof |
| CN111629742A (en) * | 2017-11-20 | 2020-09-04 | 株式会社爱茉莉太平洋 | Composition comprising green tea extract with increased polysaccharide content as active ingredient |
| CN109953145A (en) * | 2017-12-23 | 2019-07-02 | 宜兴市瑞优娜玫瑰产业有限公司 | A kind of preparation method of rose tea |
| CN112996526A (en) * | 2018-11-05 | 2021-06-18 | 株式会社爱茉莉太平洋 | Green tea extract with variable component content and composition containing the same |
| CN112106856A (en) * | 2020-08-31 | 2020-12-22 | 曲水净土玫瑰产业开发有限公司 | Preparation method of rose black tea solid beverage |
Non-Patent Citations (1)
| Title |
|---|
| 宗宁宇: "玫瑰花、果、叶不同极性部位活性研究", 中国优秀硕士学位论文全文数据库, no. 6, pages 016 - 332 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113896751A (en) * | 2021-11-19 | 2022-01-07 | 成都农业科技中心 | Punicalagin purification method and application thereof in preparation of alpha-glucosidase inhibitor |
| CN115769893A (en) * | 2022-12-02 | 2023-03-10 | 中南林业科技大学 | Polyphenol additive capable of reducing glycemic index of food and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113575946B (en) | 2024-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113575946A (en) | A composition for inhibiting absorption of sugar and fat | |
| CN114403403B (en) | Jelly with fat and weight reducing effects and preparation method thereof | |
| CN109394895A (en) | A kind of yellow mulberry tea and preparation method | |
| CN112369577A (en) | Sugar-resistant beauty composition and preparation method thereof | |
| CN107114508A (en) | A kind of organic Se-rich probiotics black tea and its preparation | |
| CN110226749A (en) | One grows tea gel food and preparation method thereof | |
| CN104286818B (en) | A kind of salad dressing containing Pollen Maydis and preparation method thereof | |
| JP5984512B2 (en) | Use of fermented soybean composition and food and drink | |
| CN101999580B (en) | Delicious weight-reducing pasty food | |
| CN111264877A (en) | Preparation method of medicinal and edible high-fiber functional food | |
| CN112704717A (en) | Stomach-invigorating medicinal and edible composition for assisting treatment of advanced digestive tract tumor | |
| CN110279050A (en) | A kind of pectase beverage of detoxicating intestine and preparation method thereof | |
| CN104509748A (en) | Chicken feed additive and preparation method thereof | |
| CN111733038A (en) | Cistanche health-care wine and preparation method thereof | |
| CN104884066B (en) | Composition for inhibiting amylase activity containing chitosan oligosaccharide | |
| CN112961883A (en) | High-activity heat-resistant white kidney bean amylase inhibitor and preparation method thereof | |
| CN108660174B (en) | Sesame bioactive peptide for resisting fatigue and promoting intestinal probiotic proliferation | |
| TW202106326A (en) | A preparation method of a guarana fermentation liquid and an use for guarana fermentation liquid | |
| CN111134324A (en) | Composition for improving and balancing intestinal microorganisms and preparation method thereof | |
| CN109275714A (en) | A kind of relieving alcoholism and protecting liver Yoghourt and preparation method thereof | |
| CN114982975B (en) | Processing method of slowly digestible starch food for hyperglycemia and diabetes patients and product thereof | |
| CN113462510A (en) | Liqueur for reducing blood sugar and preparation process thereof | |
| CN116211909B (en) | Chinese mugwort polyphenol extract with lipid-lowering effect and preparation method and application thereof | |
| CN109907242B (en) | Composition for reducing visceral fat based on microencapsulated red yeast rice and preparation method thereof | |
| CN118319998A (en) | Blood lipid-lowering fermented tea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |